A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia.
We compared the effectiveness and safety of ceftazidime and cefepime in hospitalized patients with community-acquired pneumonia. The 148 enrolled patients received 2 g ceftazidime three times daily or 2 g cefepime twice daily. The clinical success rate was the same for both drugs. Even the microbiological effectiveness was similar. Both drug regimens were well tolerated. We conclude that 2 g ceftazidime three times daily were as effective as 2 g cefepime twice daily for the treatment of community-acquired pneumonia in hospitalized patients. The cost of ceftazidime treatment was, however, higher than the cost of cefepime treatment.
Bonfitto
P
P
Division of Pneumology - S. Michele M. Laureto Hospital, Putignano, Italy.
Lamorgese
V
V
De Vietro
T
T
Malerba
M
M
Rizzello
L
L
Scoditti
S
S
Zuin
R
R
D000368:Aged; D000077723:Cefepime; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004334:Drug Administration Schedule; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D016896:Treatment Outcome
D002511:Cephalosporins; D000077723:Cefepime; D002442:Ceftazidime